The financials
Pfizer by the numbers
Pfizer (PFE) reported revenue of $15.0B in Q2 2026 (quarter ended Jun 28, 2026), up 2.6% from the same quarter a year earlier. That came with a gross margin of 73% and net loss of $248M. For the full year FY2025, revenue was $62.6B (−1.6% year on year) and net income $7.77B. Its largest product in Q2 2026 was Eliquis at $2.42B, 16% of the disclosed total, just ahead of Vyndaqel at 11%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $15.0B | $14.7B | +2.6% |
| Gross profit | $10.9B | $10.9B | +0.6% |
| Net income | −$248M | $2.91B | to a loss |
| Diluted EPS | −$0.04 | $0.51 | to a loss |
| Product | Revenue | Share |
|---|---|---|
| Eliquis | $2.42B | 16% |
| Vyndaqel | $1.76B | 11% |
| Prevnar Prevenar Family | $1.34B | 8.6% |
| Ibrance | $1.06B | 6.8% |
| All Other Hospital And Biosimilars | $952M | 6.1% |
| Other Primary Care Products | $699M | 4.5% |
| Padcev | $667M | 4.3% |
| Other Specialty Care | $566M | 3.6% |
| Xtandi | $534M | 3.4% |
| Royalty | $474M | 3.1% |
| Nurtec ODT Vydura | $421M | 2.7% |
| Pfizer Centre One | $373M | 2.4% |
| Oncology Biosimilars | $359M | 2.3% |
| Lorbrena | $354M | 2.3% |
| Other Oncology Products | $338M | 2.2% |
| Comirnaty | $261M | 1.7% |
| Xeljanz | $251M | 1.6% |
| Braftovi Mektovi | $223M | 1.4% |
| Inlyta | $218M | 1.4% |
| Abrysvo | $208M | 1.3% |
| Zavicefta | $199M | 1.3% |
| Adcetris | $196M | 1.3% |
| Inflectra | $171M | 1.1% |
| Orgovyx | $146M | 0.9% |
| Enbrel | $142M | 0.9% |
| Octagam | $138M | 0.9% |
| Tukysa | $138M | 0.9% |
| FSMEIMMUN Tico Vac | $132M | 0.9% |
| Sulperazon | $116M | 0.7% |
| Bosulif | $113M | 0.7% |
| Cresemba | $106M | 0.7% |
| Cibinqo | $94M | 0.6% |
| Genotropin | $94M | 0.6% |
| Elrexfio | $89M | 0.6% |
| Talzenna | $57M | 0.4% |
| Zithromax Zmax | $42M | 0.3% |
| Tivdak | $34M | 0.2% |
| Paxlovid EUA Labeled | $21M | 0.1% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $15.51B (+4.5%)
Orgovyx grew +51% year on yearPaxlovid EUA Labeled -95% year on year
Segment Latestquarter on quarteryear on year
- Eliquis$2.42B$2.42BQoQ +12%year on year +21%+12%+21%
- Vyndaqel$1.76B$1.76BQoQ +10.0%year on year +9.1%+10.0%+9.1%
- Prevnar Prevenar Family$1.34B$1.34BQoQ -21%year on year -3.3%-21%-3.3%
- Ibrance$1.06B$1.06BQoQ +5.0%year on year +0.86%+5.0%+0.86%
- All Other Hospital And Biosimilars$952.0M$952.0MQoQ -0.10%year on year +1.9%-0.10%+1.9%
- Other Primary Care Products$699.0M$699.0MQoQ +6.9%year on year -4.4%+6.9%-4.4%
- Padcev$667.0M$667.0MQoQ +13%year on year +23%+13%+23%
- Other Specialty Care$566.0M$566.0MQoQ -2.2%year on year +25%-2.2%+25%
- Xtandi$534.0M$534.0MQoQ +20%year on year -5.7%+20%-5.7%
- Royalty$474.0M$474.0MQoQ +20%year on year +11%+20%+11%
- Nurtec ODT Vydura$421.0M$421.0MQoQ +19%year on year +17%+19%+17%
- Pfizer Centre One$373.0M$373.0MQoQ +29%year on year +7.2%+29%+7.2%
- Oncology Biosimilars$359.0M$359.0MQoQ -12%year on year +1.7%-12%+1.7%
- Lorbrena$354.0M$354.0MQoQ +16%year on year +41%+16%+41%
- Other Oncology Products$338.0M$338.0MQoQ -10%year on year -14%-10%-14%
- Comirnaty$261.0M$261.0MQoQ +13%year on year -31%+13%-31%
- Xeljanz$251.0M$251.0MQoQ +39%year on year -22%+39%-22%
- Braftovi Mektovi$223.0M$223.0MQoQ +28%year on year +23%+28%+23%
- Inlyta$218.0M$218.0MQoQ +1.9%year on year -10%+1.9%-10%
- Abrysvo$208.0M$208.0MQoQ +16%year on year +45%+16%+45%
- Zavicefta$199.0M$199.0MQoQ +33%year on year +22%+33%+22%
- Adcetris$196.0M$196.0MQoQ +3.2%year on year -23%+3.2%-23%
- Inflectra$171.0M$171.0MQoQ -6.0%year on year +23%-6.0%+23%
- Orgovyx$146.0M$146.0MQoQ +34%year on year +51%+34%+51%
- Enbrel$142.0M$142.0MQoQ +2.9%year on year -7.8%+2.9%-7.8%
- Octagam$138.0M$138.0MQoQ +13%year on year +44%+13%+44%
- Tukysa$138.0M$138.0MQoQ +13%year on year +4.5%+13%+4.5%
- FSMEIMMUN Tico Vac$132.0M$132.0MQoQ +63%year on year +21%+63%+21%
- Sulperazon$116.0M$116.0MQoQ -42%year on year -30%-42%-30%
- Bosulif$113.0M$113.0MQoQ -12%year on year -24%-12%-24%
- Cresemba$106.0M$106.0MQoQ -year on year -4.5%--4.5%
- Cibinqo$94.0M$94.0MQoQ +24%year on year +36%+24%+36%
- Genotropin$94.0M$94.0MQoQ +1.1%year on year -11%+1.1%-11%
- Elrexfio$89.0M$89.0MQoQ +11%year on year +4.7%+11%+4.7%
- Talzenna$57.0M$57.0MQoQ +14%year on year +24%+14%+24%
- Zithromax Zmax$42.0M$42.0MQoQ -63%year on year -25%-63%-25%
- Tivdak$34.0M$34.0MQoQ +3.0%year on year -26%+3.0%-26%
- Paxlovid EUA Labeled$21.0M$21.0MQoQ -89%year on year -95%-89%-95%
Drug Manufacturers - General
The closest names by size in the same industry